GeneFrontier Corporation

Jan 5, 2023

We hope you are as excited as we are at SynBioBeta to see what 2023 has in store for the industry. Let’s start off with a round of funding news to kick off another incredible year of synbio innovation: What’s the holy grail of biology? This startup says it’s engineerable cells, and with $200 million of new funding for their CAD platform to program genetic circuits, the manufacture ofbiological therapeutics is set to radically change. The four Asimov co-founders, from left to right: Doug Densmore, Alec Nielsen, Raja Srinivas and Chris Voigt. Moderna to acquire OriCiro Genomics for $85 million:  OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines. The Japanese company is working on cell-freesynthesis and amplification of a type of DNA molecule for use in mRNA manufacturing. Congratulations to Ganymede Bio, the cloud provider for the life sciences and manufacturing industries, who just raised $12.75 million in Series A funding to make the labof the future attainable today: "We like to say we give superpowers to scientists so they can waste less time on moving data around and instead spend more time on analyzing data and deriving novel insights," said Alan Chramiec, Ph.D., founding scientist of Ganymede Bio. Another startup, Biomica, raised $20M to advance microbiome-based therapeutics pipeline. The company will use the financing to advance its first two drug candidates selected based on high-resolution functional microbiome analysis throughPhase 1 and Phase 2 clinical trials. And last but not least, LanzaTech’s facility received £25M grant from UK Department for Transport Advanced Fuels Fund to convert waste gas into sustainable aviation fuel (SAF). The world’sfirst commercial-scale factory for transforming waste gases into sustainable jet fuel is expected to produce 102 million litres per year to propel us towards the goal of net zero emissions. With 2023 officially here, we are starting the countdown to The Global Synthetic Biology Conference. Don’t forget to grab your tickets to SynBioBeta 2023! SynBioBeta 2023 speakers: Vishaal Bhuyan is the Co-Founder & CEO of Aanika Biosciences , a company usingcustomized microbial-based tags to help their customers gain valuable insights about their supply chains. Christine Gould is the Founder & CEO of Thought For Food , the world’spioneer and leader in next-gen innovation and startup acceleration for food and agriculture. Maryanna Saenko is an early-stage venture capitalist at Future Ventures with aninterest in robotics, quantum computing, climate, synthetic biology, aerospace, and the future of food. Nathan Clark is the co-founder of Ganymede Bio , one of the fastest-growingsoftware startups in biotech focused on integrating wet lab instruments and cloud-based workflows. SynBioBeta 2023 Sponsors/Exhibitors/Partners: Telesis Bio empowers researchers with end-to-end solutions and tools they need torapidly and securely design, code, and create synthetic DNA. Quartzy is a cloud-based platform that allows laboratories to streamline theircommunications, manage inventory, and purchase what they need to hit their milestones faster. Ribbon Biolabs is serving the growing need for synthetic DNA as a fundamentalcomponent for innovation in biotechnology and biopharma. GeneFrontier Corporation is focusing on biopharmaceutical R&D supportbusiness with innovative products and services especially in protein based biologics. Innovation news SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant. The company, which is pioneering CRISPR-based microbial gene therapies, has added a new technology to its portfolio that provides a highly selective way totarget individual bacterial strains for killing. TeselaGen Biotechnology launches Starter Edition of its cloud-based software platform for biology workflows: "With the Starter Edition, small groups now have greater access to some of the most powerful,design-and-build tools as larger organizations, helping them to innovate faster and accelerate product development," said TeselaGen CEO Eduardo Abeliuk. Ribbon Biolabs reaches key milestone with automation of InfiniSynthᵀᴹ platform for commercial-scale, unlimited length DNA synthesis. EnPlusOne Bio to commercialize the RNA synthesis tech invented by George Church. The Wyss Institute for Biologically Inspired Engineering at Harvard University is partnering with Northpond Labs to launch EnPlusOne Biosciences tounlock new RNA-based drugs, vaccines, and gene-editing therapies. Safety Sells: For-profit investing into civilizational resilience. Friederike Grosse-Holz, who will be speaking at SynBioBeta 2023, outlines possible avenues for for-profit capital to contribute to building a more resilientcivilization, specifically by improving food security and biosecurity. Regards,